ARTICLE | Company News
Hyperion gains on Ravicti update
January 17, 2013 1:31 AM UTC
Hyperion Therapeutics Inc. (NASDAQ:HPTX) said FDA told the company to expect a delay on a decision for an NDA for Ravicti glycerol phenylbutyrate because it is "continuing to work on label and post-marketing requirements in connection" with the application. The news sent shares of Hyperion up $2.32 (19%) to $14.32 on Wednesday. Ravicti is under review for the management of chronic urea cycle disorders, with a Jan. 23 PDUFA date. ...